Biogen Inc.

NasdaqGS:BIIB 주식 보고서

시가총액: US$25.3b

Biogen 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chris Viehbacher

최고 경영자

US$4.1m

총 보상

CEO 급여 비율39.3%
CEO 임기2yrs
CEO 소유권0.005%
경영진 평균 재임 기간4.5yrs
이사회 평균 재임 기간4.4yrs

최근 관리 업데이트

Recent updates

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

CEO 보상 분석

Chris Viehbacher 의 보수는 Biogen 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$2b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$4mUS$2m

US$1b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$3b

Dec 31 2022US$30mUS$154k

US$3b

보상 대 시장: Chris 의 총 보상 ($USD 4.07M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 12.87M ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Chris Viehbacher (63 yo)

2yrs

테뉴어

US$4,069,913

보상

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...


리더십 팀

이름위치테뉴어보상소유권
Christopher Viehbacher
President2yrsUS$4.07m0.0048%
$ 1.2m
Michael McDonnell
Executive VP & CFO4.3yrsUS$7.17m0.013%
$ 3.4m
Nicole Murphy
Head of Pharmaceutical Operations & Technology2.8yrsUS$5.71m0.0066%
$ 1.7m
Susan Alexander
Executive VP & Chief Legal Officer18.8yrsUS$6.70m0.035%
$ 9.0m
Rachid Izzar
Head of Global Product Strategy & Commercialization3.8yrsUS$5.45m0.0067%
$ 1.7m
Robin Kramer
Senior VP & Chief Accounting Officer6yrs데이터 없음0.0043%
$ 1.1m
Stephen Amato
Head of Investor Relationsless than a year데이터 없음데이터 없음
Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs4.8yrs데이터 없음데이터 없음
Adam Keeney
Executive VP & Head of Corporate Development1.6yrs데이터 없음0.00045%
$ 114.0k
Ginger Gregory
Executive VP & Chief Human Resources Officer7.3yrsUS$5.08m0.0093%
$ 2.4m
Alisha Alaimo
President & Head of North America7.3yrs데이터 없음데이터 없음
Anabella Villalobos
Head of Biotherapeutics & Medicinal Sciences7.3yrs데이터 없음데이터 없음

4.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: BIIB 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Christopher Viehbacher
President2yrsUS$4.07m0.0048%
$ 1.2m
Stephen Sherwin
Independent Director14.7yrsUS$435.32k0.013%
$ 3.3m
William Hawkins
Independent Director5.4yrsUS$425.73k0.0044%
$ 1.1m
Caroline Dorsa
Independent Chair of the Board14.8yrsUS$646.13k0.017%
$ 4.3m
Eric Rowinsky
Independent Director14.7yrsUS$418.02k0.014%
$ 3.6m
Maria Freire
Independent Director3.4yrsUS$412.90k0.0031%
$ 772.4k
Lloyd Minor
Directorsless than a year데이터 없음데이터 없음
Monish Patolawala
Independent Directorless than a year데이터 없음0.00092%
$ 233.0k
Jesus Mantas
Independent Director5.4yrsUS$433.23k0.0051%
$ 1.3m
Susan Langer
Independent Director1.4yrsUS$334.53k0.0019%
$ 478.6k

4.4yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: BIIB 의 이사회경험(평균 재직 기간 4.4 년)으로 간주됩니다.